Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome
DiscussionThese findings demonstrate that chronic InRapa administration is able to exert a neuroprotective effect on Ts65Dn hippocampus by reducing AD pathological hallmarks and by restoring protein homeostasis, thus ultimately resulting in improved cognition. Results are discussed in term of a potential novel targeted therapeutic approach to reduce cognitive decline and AD-like neuropathology in DS individuals.
Source: Translational Neurodegeneration - Category: Neurology Source Type: research
More News: Alzheimer's | Brain | Dementia | Down's Syndrome | Insulin | Laboratory Medicine | Neurology | Pathology